Business Description
Acrivon Therapeutics is a clinical-stage company focused on developing cancer treatments matched to the patients most likely to respond to them. It uses a proprietary platform called AP3 to analyze tumor biology and identify which patients are best suited for each therapy. Its most advanced drug candidate, ACR-368, targets key proteins involved in DNA damage response and is being studied in endometrial cancer, platinum-resistant ovarian cancer, and certain head and neck and anal cancers. Founded in 2018 and headquartered in Watertown, Massachusetts, the company is also advancing additional small molecule candidates targeting other cancer-related pathways.
